Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

December 30, 2024

Conditions

Oral MucositisLymphomaMultiple MyelomaHematologic Cancer

Interventions

DRUG

MIT-001

Corresponding dose of MIT-001 IV injection during 0.5\~1hr

DRUG

normal saline

normal saline IV injection

Trial Locations (2)

Seoul ST. Mary's Hospital, Seoul

Yeouido ST. Mary's Hospital, Seoul